Fig. 4

HGF signature ranks the predicted sensitivity of GBM-PDX models to MET inhibitors. a Forty GBM patient-derived tumor models were analyzed by using the HGF signature as a biomarker of suitability for treatment with MET inhibitors. Models with high HGF expression are clustered together at right side of the heatmap, suggesting a common molecular profile and a high sensitivity to MET-targeted therapy. b GBM models G116 and G91 were used to validate the therapeutic efficacy of V-4084. G116, ranked the most sensitive to MET inhibitor, showed significant response to V-4084 treatment; G91, ranked the insensitive, showed no response. c HGF, MET, and EGFR mRNA expression levels in G116 and G91 tumor models